Matchbook

The dossier request concerns a commercial entity named Matchbook. However, the only supplied evidence is a press release about Debiopharm's pre-clinical antibody-drug conjugate linker research (MultiLINK / MLINK Select, MLINK Duo, MLINK HiSol), presented at World ADC San Diego 2026. That document contains no reference to Matchbook, no company description, no product line, no ownership information, and no headquarters or founding details. Because the evidence does not establish that Matchbook is a brand, company, product platform, retailer, or trademarked commercial offering, no reliable brand identity can be constructed. Writing a full dossier would require inventing facts, which is not permitted. The entry is therefore flagged for review, and the fields that would normally carry brand identity, offerings, industry classification, ownership, and history are left empty rather than guessed. If a source describing the intended Matchbook entity (for example an official website, a Wikipedia brand article, or a corporate filing) is supplied, this dossier can be rebuilt with a proper summary, history, milestones, products, and taxonomy placement.

1. 1Debiopharm's Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistancefinanznachrichten.de
2. 2Dermot Desmond’s Betdaq acquired by Matchbook in betting exchange dealheraldscotland.com
3. 3Matchbook acquires Betdaq in unification of two of the longest-established names in exchange bettingigamingbusiness.com
4. 4Matchbook completes takeover of Betdaq - AOLaol.co.uk